Michael Davidson, MD, FACC, FACP, FNLA

Michael Davidson, MD, FACC, FACP, FNLA

Clinical Professor

Director of Preventive Cardiology

The University of Chicago Hospitals and Clinic

Pritzker School of Medicine

Chicago, Illinois

Related Videos

The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100mg/dL to 30mg/dL. In light of this, how should the lipid specialist deploy PCSK9 inhibitors? Video

The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100mg/dL to 30mg/dL. In light of this, how should the lipid specialist deploy PCSK9 inhibitors?

From a lipid specialist’s perspective, do the results from the ODYSSEY Outcomes Trial suggest the need to be more focused on achieving absolute target levels of LDL-C or relative percentage reductions in LDL-C levels? Video

From a lipid specialist’s perspective, do the results from the ODYSSEY Outcomes Trial suggest the need to be more focused on achieving absolute target levels of LDL-C or relative percentage reductions in LDL-C levels?

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist? Video

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting? Video

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

You have introduced the concept of progressive atherosclerotic burden to characterize the multiplicity of biologic, metabolic, and clinical markers in a CV risk profile. How do you apply this aggregated risk to patient selection for PCSK9 inhibitors? Video

You have introduced the concept of progressive atherosclerotic burden to characterize the multiplicity of biologic, metabolic, and clinical markers in a CV risk profile. How do you apply this aggregated risk to patient selection for PCSK9 inhibitors?